搜索临床试验以:维奈托克加 HMA
总计6697个结果
-
Dartmouth-Hitchcock Medical Center完全的
-
Janssen Research & Development, LLC批准上市
-
CardresearchCytel Inc.; Cardresearch - Cardiologia Assistencial e de Pesquisa LTDA未知
-
University of Michigan Rogel Cancer CenterCelgene; Onyx Therapeutics, Inc.完全的
-
University of ReadingBiotechnology and Biological Sciences Research Council; Quercegen Pharmaceuticals撤销
-
Grupo Rehabilitacion en SaludUniversidad de Antioquia完全的
-
Accelerated Community Oncology Research NetworkEli Lilly and Company; Genentech, Inc.完全的
-
Catholic University of the Sacred Heart未知
-
Stanford UniversityNational Institutes of Health (NIH)主动,不招人
-
Unity Health TorontoUniversity of Manitoba; University of British Columbia; Canadian Institutes of Health Research... 和其他合作者完全的
-
Xijing HospitalXi'an Central Hospital; Shangluo Central Hospital; Baoji Central Hospital; Ankang Central Hospital; Yan'an University Affiliated Hospital 和其他合作者完全的
-
CHEOL WHAN LEE, M.D., Ph.DMedtronic; CardioVascular Research Foundation, Korea; Chong Kun Dang Pharmaceutical Corp.终止
-
Centre for Global Health Research, GhanaLondon School of Hygiene and Tropical Medicine完全的
-
Pakistan Institute of Living and LearningStanley Medical Research Institute; Dow University of Health Sciences; Abbasi Shaheed Hospital; Karwan...完全的
-
University of Roma La SapienzaIstituto Superiore di Sanità未知
-
Mansoura Integrated Fertility Center未知
-
St Stephens Aids Trust完全的
-
Mayo ClinicNational Cancer Institute (NCI)招聘中
-
Novartis Pharmaceuticals完全的哮喘德国, 印度, 以色列, 波兰, 阿根廷, 俄罗斯联邦, 希腊, 塞尔维亚, 火鸡, 匈牙利, 墨西哥, 秘鲁, 斯洛伐克, 捷克语, 南非, 台湾, 越南, 西班牙, 哥伦比亚, 智利
-
Temple UniversityPfizer; Abbott终止
-
University of Cape TownWorld Health Organization; Medical Research Council, South Africa; Global Fund完全的
-
University of ManitobaWinnipeg Regional Health Authority; MED XL Inc完全的
-
Hospital de Clinicas de Porto AlegreFinanciadora de Estudos e Projetos完全的
-
National Taiwan University HospitalNational Science Council, Taiwan; Department of Health, Executive Yuan, R.O.C. (Taiwan)完全的
-
National Cancer Institute (NCI)主动,不招人BLAST MRD AML-2:在标准疗法中加入 PD-1 阻断以靶向急性髓系白血病中可测量的残留病灶 2-抗 PD-1 派姆单抗联合阿扎胞苷和维奈托克作为一线治疗的随机 2 期研究患有急性髓性白血病急性髓性白血病 | 既往骨髓增生异常综合征引起的急性髓性白血病 | 继发性急性髓性白血病 | 细胞毒治疗后急性髓系白血病美国
-
Holy Stone Healthcare Co., Ltd尚未招聘
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)完全的
-
University of WashingtonAstraZeneca撤销IVA 期肺癌 AJCC v8 | IVB 期肺癌 AJCC v8 | IV 期肺癌 AJCC v8 | 广泛期肺癌小细胞癌美国